Oral compositions
AssigneeSymrise AG
InventorsJakob Ley, Sabine Widder, Veronika Somoza, Barbara Rohm, Matthias Zaunschirm, Gerhard Krammer
Life of this patent
Estimating the term…
Abstract
Suggested are new compositions for oral ingestion, comprising at least one active agent from the group of alkamides. The compositions which are orally ingested reduce the uptake of free fatty acids in the adipocytes and at the same time stimulate the release of serotonin and dopamine, which leads to a reduction of appetite, a feeling of satiety and a positive mood. In doing so, the new compositions are thus perfectly suitable to counteract any undesired gain of weight.
Claims11
Compositions for oral ingestion, comprising at least one alkamide selected from the group consisting of 2E,4E-decadienic acid-N-isobutylamide (trans-pellitorine);
- 2E,4Z-decadienic acid-N-isobutylamide (cis-pellitorine);
- 2Z,4Z-decadienic acid-N-isobutylamide;
- 2Z,4E-decadienic acid-N-isobutylamide, 2E,4E-decadienic acid-N-([2S]-2-methylbutyl)amide;
- 2E,4E-decadienic acid-N-([2S]-2-methylbutyl)amide;
- 2E,4E-decadienic acid-N-([2R]-2-methylbutylamide);
- 2E,4Z-decadienic acid-N-(2-methylbutyl)amide;
- 2E,4E-decadienic acid-N-piperidine (achilleamide);
- 2E-decenoic acid-N-isobutylamide;
- 2E,6Z,8E-decatrienoic acid N-isobutylamide (spilanthol);
- 2E,6Z,8E-decatrienoic acid N-([2S]-2-methylbutyl)amide (homospilanthol);
- 2E,6Z,8E-decatrienoic acid-N-([2R]-2-methylbutyl)amide;
- 2E-decen-4-inoic acid-N-isobutyl amide;
- 2Z-decen-4-inoic acid N-isobutyl amine;
- 2E,6Z,8E,10E-dodecatetraenoic acid N-(2-methylpropyl)amide (α-sanshool);
- 2E,6Z,8E,10E-dodecatetraenoic acid N-(2-hydroxy-2-methylpropyl)amide (α-hydroxysanshool);
- 2E,6E,8E,10E-dodecatetraenoic acid N-(2-hydroxy-2-methylpropyl)amide (β-hydroxysanshool;
- 2E,4E,8Z,10E,12E-tetradecapentaenoic acid N-(2-hydroxy-2-methylpropyl)amide (γ-hydroxysanshool);
- 2E,4E,8E,10E,12E-tetradecapentaenoic acid N-(2-hydroxy-2-methylprypyl)amide (γ-hydroxyisosanshool);
- 2E,4E,8Z,10E,12E-tetradecapentaenoic acid N-(2-methyl-2-propenyl)amide (y-dehydrosanshool);
- 2E,4E,8Z,10E,12E-tetradecapentaenoic acid N-(2-methylpropyl)amide (y-sanshool);
- 2E,4E,8Z,11Z-tetradecatetraenoic acid N-(2-hydroxy-2-methylpropyl)amide (bungeanool), 2E,4E,8Z,11E-tetradecatetraenoic acid N-(2-hydroxy-2-methylpropyl)amide (isobungeanool), 2E,4E,8Z-tetradecatrienoic acid N-(2-hydroxy-2-methylpropyl)amide (dihydrobungeanool) and 2E,4E-tetradecadienoic acid N-(2-hydroxy-2-methylpropyl)amide (tetrahydrobungeanool).
A non-therapeutic process for the reduction of appetite and/or to create a feeling of satiety and/or to reduce caloric resorption and/or for mood-enhancing purposes, wherein a composition comprising an effective amount of at least one alkamide is orally administered to a human or an animal being.
9-11. (canceled)
Use of alkamides as means to be orally ingested to reduce appetite and/or create a feeling of satiety and/or reduce the resorption of calories and/or for mood-enhancing purposes.
13-15. (canceled)
Dependencies are inferred from the claim text.